# reload+after+2024-01-21 00:45:09.967579
address1§12390 El Camino Real
city§San Diego
state§CA
zip§92130
country§United States
phone§858 794 8889
fax§858 704 8311
website§https://halozyme.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
fullTimeEmployees§393
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.', 'age': 60, 'title': 'President, CEO & Director', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 1446930, 'exercisedValue': 2465334, 'unexercisedValue': 66732772}, {'maxAge': 1, 'name': 'Ms. Nicole  LaBrosse', 'age': 40, 'title': 'Senior VP & CFO', 'yearBorn': 1983, 'fiscalYear': 2022, 'totalPay': 727038, 'exercisedValue': 0, 'unexercisedValue': 3142203}, {'maxAge': 1, 'name': 'Dr. Michael J. LaBarre Ph.D.', 'age': 59, 'title': 'Senior VP & Chief Technical Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 723237, 'exercisedValue': 0, 'unexercisedValue': 13662016}, {'maxAge': 1, 'name': 'Mr. Mark  Snyder Esq.', 'title': 'Chief Legal Officer', 'fiscalYear': 2022, 'totalPay': 742776, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Cortney  Caudill M.B.A.', 'title': 'Chief Operations Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Tram  Bui', 'title': 'Head of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Amy Marinne Fox', 'title': 'Chief Human Resources Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Steve  Knowles MBBS', 'title': 'Chief Medical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Christopher  Bryant Ph.D.', 'age': 62, 'title': 'Chief Manufacturing Officer & Head of Technical Operations', 'yearBorn': 1961, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kristin  Schwartzbauer', 'title': 'Head of Quality', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§4
boardRisk§1
compensationRisk§2
shareHolderRightsRisk§3
overallRisk§2
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.225
priceToSalesTrailing12Months§5.9423876
currency§USD
dateShortInterest§1702598400
forwardEps§3.72
pegRatio§0.46
exchange§NMS
quoteType§EQUITY
shortName§Halozyme Therapeutics, Inc.
longName§Halozyme Therapeutics, Inc.
firstTradeDateEpochUtc§1079447400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§aa1169be-b80b-3480-8b26-f57e5230a087
gmtOffSetMilliseconds§-18000000
targetHighPrice§72.0
targetLowPrice§28.0
targetMeanPrice§50.3
targetMedianPrice§48.0
recommendationMean§2.5
recommendationKey§buy
numberOfAnalystOpinions§10
quickRatio§6.082
earningsGrowth§0.386
grossMargins§0.66726
ebitdaMargins§0.50751996
trailingPegRatio§None
